MNTA $16.72 0.11 (0.7%)

    MNTA Profile

    MNTA trades on the NASDAQ.

    MEMBERSHIP
    --
    SECTOR
    Health Care
    MARKET CAPITALIZATION

    $2 Billion

    Small-Cap
    Momenta is a biotechnology company focused on the characterization and development of innovative drugs in autoimmune diseases. Its legacy business includes complex generic versions of MS drug Copaxone and anticoagulant Lovenox, and it receives royalties for these products through a partnership with Novartis. While biosimilar versions of Humira and Eylea are in the pipeline, Momenta terminated future development in generics/biosimilars in 2018. Several innovative drugs, including M281, M254, and M230, are in development to treat rare autoimmune diseases.

    MNTA Earnings

    EPS

    -0.45

    P/E

    --

    Q2 Earnings for Apr, May & Jun

    Fri, Aug 2, 2019

    Since Earnings Report

    MNTA +45.6%

    Q3 Earnings for Jul, Aug & Sep

    Thu, Oct 31, 2019

    Since Earnings Report

    MNTA +6.5%

    MNTA Dividend

    Dividend Yield

    0.00%

    Dividend Rate

    $0.00

    Ex-Dividend Date

    --

    Dividend Pay Date

    --

    Dividend Frequency

    --

    Dividend Payments

    --

    MNTA Charts

    52WL $9.51
    52WH $18.39
    All-Time $34.60


    MNTA Industry Competitors


    DRUG MANUFACTURERS
    Novartis AG
    Astrazeneca
    GlaxoSmithKline
    Bausch Health Companies Inc. Common Stock
    Elanco Animal Health
    Catalent Inc
    Canopy Growth Corporation Common Stock
    Dr. Reddy's Laboratories Ltd Common Stock
    The Medicines Co
    Horizon Pharma PLC



    Symbol MC DY Price Day YTD
    MNTA $1.79 0.00% $16.72 -0.7% 48.0%






        TOP    




    info@symbolsurfing.com


    Symbol Surfing

    ©2019 Symbol Surfing All Rights Reserved.

    Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.

    Cookies Policy Terms Of Service Privacy Policy